Myelodysplastic syndromes in the United States: an update for clinicians

References

• Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer. 2012;12:849–59.
   PubMed Web of Science ®Google Scholar
• Scott BL, Deeg HJ. Myelodysplastic syndromes. Annu Rev Med. 2010;61:345–58.
   PubMed Web of Science ®Google Scholar
• Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125(7 Suppl):S2–5.
   Web of Science ®Google Scholar
• Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24:287–94.
   PubMed Web of Science ®Google Scholar
• Steensma DP. Historical perspectives on myelodysplastic syndromes. Leuk Res. 2012;36:1441–52.
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs.Blood.2008;112:45–52.
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–10.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100:1542–51.
   PubMed Web of Science ®Google Scholar
• Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at: http://www.cibmtr.org (accessed 12 August 2013).
   Google Scholar
• Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm. Blood. 2011;117:7121–5.
   PubMed Web of Science ®Google Scholar
• Steensma DP. Are myelodysplastic syndromes ‘cancer’?Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006;30:1227–33.
   Google Scholar
• Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104: 2263–8.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28: 2847–52.
   PubMed Web of Science ®Google Scholar
• Bain BJ. Di Guglielmo and his syndromes. Br J Haematol. 2003;120: 939–43.
   PubMed Web of Science ®Google Scholar
• Hamilton-Paterson JL. Pre-leukaemic anaemia. Acta Haematol. 1949;2: 309–16.
   PubMed Web of Science ®Google Scholar
• Block M, Jacobson LO, Bethard WF. Preleukemic acute human leukemia. J Am Med Assoc. 1953;152:1018–28.
   PubMed Web of Science ®Google Scholar
• Saarni MI, Linman JW. Preleukemia. The hematologic syndrome preceding acute leukemia. Am J Med. 1973;55:38–48.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.
   PubMed Web of Science ®Google Scholar
• Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name?Hematology Am Soc Hematol Educ Program. 2009:645–55.
   Google Scholar
• Brunning R, Porwit A, Swerdlow S, Campo E. Myelodysplastic syndromes/neoplasms overview. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumors. 4th ed. Lyon: IARC; 2008. p. 88–93.
   Google Scholar
• Davids MS, Steensma DP. The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther. 2010;10:309–19.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Mohamedali AM, Mufti GJ. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol. 2013;162:587–605.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27:1275–82.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090–8.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9.
   PubMed Web of Science ®Google Scholar
• Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012;26:542–5.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–95.
   PubMed Web of Science ®Google Scholar
• Issa JP. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood. 2013;121:3811–17.
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114:2764–73.
   PubMed Web of Science ®Google Scholar
• Koury MJ, Rhodes M. How to approach chronic anemia. Hematology Am Soc Hematol Educ Program. 2012;2012:183–90.
   PubMedGoogle Scholar
• Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2012;2012:191–7.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–61.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538–43.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:692–701.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2013;11:838–74.
   PubMed Web of Science ®Google Scholar
• Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes risk assessment calculator: The Myelodysplastic Syndromes Foundation. Available at: http://www.mds-foundation.org/ipss-r-calculator/ (accessed 8 July 2013).
   Google Scholar
• Cluzeau T, Mounier N, Richez V, Karsenti J-M, Legrand F, Mannone L, et al. Azacitidine overcomes prognosis impact of poor and very poor IPSS-Revised in RAEB-2 patients but not in AML patients. American Society for Hematology Annual Meeting; 8–11 December 2012; Atlanta, GA, USA. Abstract 2813.
   Google Scholar
• Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, et al. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. J Clin Oncol. 2013;31:3557–64.
   PubMed Web of Science ®Google Scholar
• Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011;44:53–7.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30:3376–82.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64.
   PubMed Web of Science ®Google Scholar
• Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997–2004.
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Deeg HJ. Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Blood Rev. 2012;26:247–54.
   PubMed Web of Science ®Google Scholar
• Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607–13.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–40.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29:1987–96.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106: 1794–803.
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–85.
   PubMed Web of Science ®Google Scholar
• Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662–70.
   PubMed Web of Science ®Google Scholar
• Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.
   PubMed Web of Science ®Google Scholar
• Allogeneic hematopoietic stem cell transplantation for the treatment of myelodysplastic syndromes: Centers for Medicare and Medicaid Services. Available at: http://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Allogeneic-Hematopoietic-Stem-Cell-Transplantation-for-the-treatment-of-Myelodysplastic-Syndromes-.html (accessed 30 July 2013).
   Google Scholar
• Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14(9 Suppl):8–15.
   PubMed Web of Science ®Google Scholar
• US transplant data by disease report: Center for International Blood and Marrow Transplant. Available from: http://bloodcell.transplant.hrsa.gov/RESEARCH/Transplant_Data/US_Tx_Data/Data_by_Disease/national.aspx (accessed 30 July 2013).
   Google Scholar
• Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013;122:1974–82.
   PubMed Web of Science ®Google Scholar
• McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878–87.
   PubMed Web of Science ®Google Scholar
• Atallah E, Pedersen T, Warlick E, Dircks A, Weisdorf D, Horowitz M, et al. The outcome of hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) in adults ≥ 65 years of age: first report of the coverage with evidence development (CED) in Medicare beneficiaries. American Society for Hematology Annual Meeting; Atlanta, GA: American Society for Hematology Annual Meeting; 8–11 December 2012; Atlanta, GA, USA. Abstract 1983.
   Google Scholar
• Atallah E, Bylow K, Troy J, Saber W. Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic cell transplantation (allo HSCT). Curr Hematol Malig Rep. 2014;9:57–65.
   PubMed Web of Science ®Google Scholar
• Logan B, Leifer E, Bredeson C, Horowitz M, Ewell M, Carter S, et al. Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clin Trials. 2008;5:607–16.
   PubMed Web of Science ®Google Scholar
• Warlick ED. Epidemiology of myelodysplastic syndromes: many questions remain. Leuk Lymphoma. 2011;52:163–4.
   PubMed Web of Science ®Google Scholar